alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5886 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 5886

    To apply the Bank Secrecy Act to dealers in art or antiquities.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 18, 2018

  Mr. Messer introduced the following bill; which was referred to the 
                    Committee on Financial Services

_______________________________________________________________________

                                 A BILL

 
    To apply the Bank Secrecy Act to dealers in art or antiquities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Illicit Art and Antiquities 
Trafficking Prevention Act''.

SEC. 2. APPLICATION OF BANK SECRECY ACT TO DEALERS IN ART OR 
              ANTIQUITIES.

    (a) In General.--Section 5312(a)(2) of title 31, United States 
Code, is amended--
            (1) in subparagraph (Y), by striking ``or'' at the end;
            (2) in subparagraph (Z), by striking the period and 
        inserting ``; or''; and
            (3) by adding at the end the following:
                    ``(AA) dealers in art or antiquities.''.
    (b) Rulemaking.--Not later than the end of the 180-day period 
beginning on the date of the enactment of this Act, the Secretary of 
the Treasury shall issue regulations to carry out the amendments made 
by subsection (a).
    (c) Effective Date.--Section 5312(a)(2)(AA) of title 31, United 
States Code, as added by subsection (a), shall take effect after the 
end of the 270-day period beginning on the date of the enactment of 
this Act.
                                 <all>
```
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 21-0214

STATE OF MONTANA, 

Plaintiff and Appellee, 

v. 

JOSHUA GLEN REID,

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time to 

produce transcripts on appeal, and good cause appearing, Court 

Reporter Cindy Prindiville is granted an extension of time to and 

including January 7, 2022, within which to prepare, file, and serve the 

transcripts requested on appeal.

No further extensions will be granted.

The Clerk shall serve a copy of this Order upon the district court 

and the court reporter.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

November 16 2021

11/16/2021

Case Number: DA 21-0214
<PAGE>


                              Sonic Foundry, Inc.
                           Annual Report on Form 10-K
                     For the Year Ended September 30, 2002


EXHIBIT 99.1

                        CERTIFICATION OF PERIODIC REPORT


     Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, the undersigned officer of Sonic Foundry, Inc. (the "Company"),
hereby certifies that:

     (1) the Company's Annual Report on Form 10-K for the period ended September
30, 2002 (the "Report") fully complies with the requirements of Section 13(a) or
15(d), as applicable, of the Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: December 27, 2002


                                       /s/ Rimas P. Buinevicius
                                       ----------------------------------------
                                       Name:  Rimas P. Buinevicius
                                       Title: Chairman, Chief Executive Officer
EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906


OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Triangle Alternative Network Incorporated (the "Company") on Form 10-Q for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), I, Gerry Shirren, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:




(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  Dated: May 15,2011
/s/ Gerry ShirrenBy:
Gerry ShirrenIts:
Chief Financial Officer
Exhibit 4.1


 





ROSETTA GENOMICS LTD.


 


AMENDMENT TO SERIES B WARRANT TO PURCHASE
ORDINARY SHARES


 


This Amendment (this
“Amendment”) to each Series B Warrant (each a “Series B Warrant,” and collectively the “Series
B Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated as of October 13, 2015, by and among
Rosetta Genomics Ltd., a company organized under the laws of the State of Israel, and the Purchasers referred to therein (the “Purchase
Agreement”), shall be effective as of the date that this Amendment is executed by the Company and the holders of Series
B Warrants constituting the Required Holders. Capitalized terms used herein and not otherwise defined shall have the meaning set
forth in the Purchase Agreement.


 


RECITALS


 


WHEREAS: the
Company has issued Series B Warrants to purchase ordinary shares of the Company, par value NIS 0.6 per share, pursuant to the Purchase
Agreement;


 


WHEREAS: the
Company has determined that it is in the best interests of the Company and its security holders to amend each Series B Warrant
to extend the Expiration Date; and


 


WHEREAS: the
Series B Warrants may be amended with the written consent of the Company and the Required Holders.


 


NOW THEREFORE:
in consideration of the premises and the mutual covenants contained in this Amendment and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:


 


1.           The definition of “Expiration
Date” set forth in Section 17(j) of the Purchase Agreement shall be amended as follows:


 


(j) “Expiration
Date” means the 120th calendar day after the Effective Date.


 


2.           This Amendment may be executed in
one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.


 


3.           Except as herein provided, all of
the terms of the Series B Warrants shall remain in full force and effect.


 


(signature page follows)


 






     


     


    

 


 


 


EXECUTED as of _____________, 2015.


 


 





	 	ROSETTA GENOMICS LTD.
	 	 	 
	 	 	 
	 	 	 
	 	By:	   
	 	Name:	Kenneth A. Berlin
	 	Title:	President and Chief Executive Officer







 


 


 


 


 





SIGNATURE
PAGE TO AMENDMENT TO SERIES B WARRANT TO PURCHASE ORDINARY SHARES]











     


     


    




 


EXECUTED as of ____________, 2015.


 


SERIES B WARRANT HOLDER:


	 	    
	 	

Printed Name of Warrant Holder






	 	 
	 	 
	 	 
	 	By:	 
	 	 	 
	 	Name:	   
	 	 	 
	 	Title:	   
	 	 	 
	 	 	 


 


 


 


 


 




SIGNATURE PAGE TO AMENDMENT TO SERIES
B WARRANT TO PURCHASE ORDINARY SHARES]
EXHIBIT 21.1
 SUBSIDIARIES  As of December 31, 2008
 1.
    
    Hillman Group Capital Trust
Organized in the State of Delaware2.
    
    Hillman Investment Company
Incorporated in the State of Delaware3.
    
    The Hillman Group, Inc.
Incorporated in the State of Delaware
 a.
    
    All Points Industries, Inc.
Incorporated in the State of Floridab.
    
    SunSource Integrated Services de Mexico S.A. de C.V.
Incorporated in Ciudad de Mexico, Mexicoc.
    
    The Hillman Group Canada, Ltd.
Incorporated in the Province of Ontario, Canadad.
    
    SunSource Technology Services, L.L.C.
Formed under the laws of the State of Delawaree.
    
    SunSub C, Inc.
Incorporated in the State of Delaware
 i.
    
    SunSub Holdings L.L.C.
Formed under the laws of the State of Delaware
Exhibit
      32.1





I,
      Dr
      David Dalton, Chief Executive Officer of Univec, Inc., certify,
      pursuant


to
      18
      U.S.C. 1350, as enacted by 906 of the Sarbanes-Oxley Act of 2002,


that:





(1)
      the Annual Report on Form 10-KSB for the annual period ended December
      31,


2004
      (the "Periodic Report") which this statement accompanies fully
      complies


with
      the requirements of Section 13(a) or 15(d) of the Securities Exchange
      Act


of
      1934; and





(2)
      the information contained in the Periodic Report fairly presents, in
      all


material
      respects, the financial condition and results of operations of
      Univec,


Inc.








Dated:
          January 11, 2006
 By:
      /s/
      David Dalton


-----------------------------------------


Dr,
      David
      Dalton, Chief Executive Officer
EXHIBIT 32.2

CERTIFICATION PURSUANT TO SECTION 906

OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CurrencySharesSMSouth African Rand Trust (the Trust) on Form 10-Q for
the period ended January 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Joseph Arruda, Chief Financial Officer of Rydex Specialized Products LLC, the Sponsor of the Trust, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Trust.

Date: March 12, 2010



|                                                     
|-----------------------------------------------------
|/s/ Joseph Arruda                                    
|Joseph Arruda*                                       
|Chief Financial Officer (principal financial officer)



|* | The Registrant is
a trust and Joe Arruda is signing in his capacity as the principal financial officer of Rydex Specialized Products LLC, the Sponsor of the Registrant.
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE>          5
<MULTIPLIER>       1,000
       
<S>                               <C>
<PERIOD-TYPE>                     9-MOS
<FISCAL-YEAR-END>                 12/31/95
<PERIOD-END>                      09/30/95
<CASH>                              24,540
<SECURITIES>                         1,233
<RECEIVABLES>                       50,623   
<ALLOWANCES>                       (1,097)   
<INVENTORY>                          4,286   
<CURRENT-ASSETS>                    80,723
<PP&E>                              60,185
<DEPRECIATION>                    (36,729)
<TOTAL-ASSETS>                     129,285
<CURRENT-LIABILITIES>               46,214
<BONDS>                                  0
<COMMON>                               530
<PREFERRED-MANDATORY>                    0
<PREFERRED>                              0
<OTHER-SE>                          76,236
<TOTAL-LIABILITY-AND-EQUITY>       129,285
<SALES>                            247,314 
<TOTAL-REVENUES>                   247,314    
<CGS>                              192,779 
<TOTAL-COSTS>                      192,779
<OTHER-EXPENSES>                    49,036
<LOSS-PROVISION>                         0
<INTEREST-EXPENSE>                       0
<INCOME-PRETAX>                      5,900  
<INCOME-TAX>                         2,360
<INCOME-CONTINUING>                  3,540
<DISCONTINUED>                           0
<EXTRAORDINARY>                          0
<CHANGES>                                0
<NET-INCOME>                         3,540
<EPS-PRIMARY>                          .34
<EPS-DILUTED>                          .34

</TABLE>
EXHIBIT 32


CERTIFICATION PURSUANT TO SECTION 906

Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, I, the
undersigned officer of the Canistel Acquisition Corporation
(the "Company"), hereby certify to my knowledge that:

The Report on Form 10-Q for the period ended March 31,
2009 of the Company fully complies, in all material respects,
with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the
Report fairly represents, in all material respects, the
financial condition and results of operations of the Company.

A signed original of this written statement required by Section
906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange
Commission or its staff upon request.


                             /s/ James M. Cassidy
                                 President and Director and
                                 Chief Executivie Officer,
                                 Chief Financial Officer and
                                 Principal Accounting Officer
Date: May 13, 2009
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                          14,032
<SECURITIES>                                         0
<RECEIVABLES>                                   15,409
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                88,000
<PP&E>                                           8,587
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 158,147
<CURRENT-LIABILITIES>                           66,845
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           222
<OTHER-SE>                                      91,055
<TOTAL-LIABILITY-AND-EQUITY>                   158,147
<SALES>                                         66,678
<TOTAL-REVENUES>                                95,649
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                39,840
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               3,164
<INCOME-PRETAX>                                 52,645
<INCOME-TAX>                                    19,873
<INCOME-CONTINUING>                             32,772
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    32,772
<EPS-PRIMARY>                                     1.50
<EPS-DILUTED>                                     1.49


</TABLE>
# Waiver of Section 1083 of the National Defense Authorization Act for Fiscal Year 2008

# Memorandum for the Secretary of State 

By the authority vested in me as President by the Constitution and the laws of the United States, including section 301 of title 3, United States Code, and section 1083(d) of the National Defense Authorization Act for Fiscal Year 2008 (the “Act”), I hereby determine that: 

- All provisions of section 1083 of the Act, if applied to Iraq or any agency or instrumentality thereof, may affect Iraq or its agencies or instrumentalities, by exposing Iraq or its agencies or instrumentalities to liability in United States courts and by entangling their assets in litigation.
- The economic security and successful reconstruction of Iraq continue to be top national security priorities of the United States. Section 1083 of the Act threatens those key priorities. If permitted to apply to Iraq, section 1083 would risk the entanglement of substantial Iraqi assets in litigation in the United States—including those of the Development Fund for Iraq, the Central Bank of Iraq, and commercial entities in the United States in which Iraq has an interest. Section 1083 also would expose Iraq to new liability of at least several billion dollars by undoing judgments favorable to Iraq, by foreclosing available defenses on which Iraq is relying in pending litigation, and by creating a new Federal cause of action backed by the prospect of punitive damages to support claims that may previously have been foreclosed. If permitted to apply to Iraq, section 1083 would have a significant financial impact on Iraq and would result in the redirection of financial resources from the continued reconstruction of Iraq and the harming of Iraq's stability, contrary to the interests of the United States.
- A waiver of all provisions of section 1083 with respect to Iraq and any agency or instrumentality of Iraq is therefore in the national security interest of the United States and will promote the reconstruction of, the consolidation of democracy in, and the relations of the United States with, Iraq.
- Iraq continues to be a reliable ally of the United States and a partner in combating acts of international terrorism. The November 26, 2007, Declaration of Principles for a Long-Term Relationship of Cooperation and Friendship between the Republic of Iraq and the United States of America confirmed the commitment of the United States and Iraq to build an enduring relationship in the political, diplomatic, economic, and security arenas and to work together to combat all terrorist groups, including al-Qaida.

Accordingly, I hereby waive all provisions of section 1083 of the Act with respect to Iraq and any agency or instrumentality thereof. 

                    You are authorized and directed to notify the Congress of this determination and waiver and the accompanying memorandum of justification, incorporated by reference herein, and to arrange for their publication in the                     **Federal Register**                    .                 

Billing code 4710-10-P

[FR Doc. 08-515

Billing code 4710-10-C
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 09-30702

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

JUAN GONZALES, also known as Hugo Daniel-Rodrigues, also known as

Miguel Ventura, also known as Ramon Olarra, also known as Daniel Hugo, also

known as Jose Ventura-Ginez, also known as Hugo Daniel,

Defendant-Appellant

Consolidated with

No. 09-30703

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

JUAN GONZALES,

Defendant-Appellant

Appeals from the United States District Court

for the Western District of Louisiana

USDC No. 6:09-CR-7-1

USDC No. 6:09-CR-57-1

United States Court of Appeals

Fifth Circuit

F I L E D

April 23, 2010

Lyle W. Cayce

Clerk

Case: 09-30702 Document: 00511090583 Page: 1 Date Filed: 04/23/2010
No. 09-30702

c/w No. 09-30703

 Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not *

be published and is not precedent except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

2

Before JOLLY, WIENER, and ELROD, Circuit Judges.

PER CURIAM:*

The Federal Public Defender appointed to represent Juan Gonzales has

moved for leave to withdraw and has filed a brief in accordance with Anders v.

California, 386 U.S. 738 (1967). Gonzales has filed a response. Our independent

review of the record, counsel’s brief, and Gonzales’s response discloses no

nonfrivolous issue for appeal. Accordingly, counsel’s motion for leave to

withdraw is GRANTED, counsel is excused from further responsibilities herein,

and the APPEALS ARE DISMISSED. See 5TH CIR. R. 42.2.

Case: 09-30702 Document: 00511090583 Page: 2 Date Filed: 04/23/2010
Dose Reconstruction 

A Closer Look at the Research Behind Your Claim 

Fact Sheet 

Q: 

A: 

What is dose reconstruction? 

Dose reconstruction is an accepted scientific method used to estimate 

how much radiation an energy employee was exposed to while working at 

Department of Energy or Atomic Weapons Employer work sites. 

Q: 

A: 

Why is NIOSH doing a dose reconstruction for my claim? 

NIOSH is responsible for providing an estimate of the energy employee’s 

radiation dose for the Department of Labor (DOL). DOL will use the final dose 

reconstruction report to make a recommended decision on your claim. 

Q: 

A: 

What information will NIOSH use for my dose reconstruction? 

NIOSH may use: film badge readings, medical x-rays, urine analysis, 

incident reports, co-worker data, environmental exposure records, technical 

documents, interview information, workplace history, and other available 

information. 

Q: 

A: 

How long will it take NIOSH to finish my dose reconstruction? 

There are many steps necessary to complete each dose reconstruction, 

and each step varies for each claim. For example, obtaining the information 

to complete the dose reconstruction estimate may take a significant 

amount of time depending on the complexity and availability of the data. 

Therefore, there is no way to predict how long each claim may take to 

complete the dose reconstruction process. 

Q: 

A: 

What if NIOSH cannot do a dose reconstruction? 

NIOSH will notify you in writing that a dose reconstruction cannot be 

completed for your claim. NIOSH will provide you with information about a 

different means of compensation that does not require a dose 

reconstruction called the Special Exposure Cohort. Further information is 

available on the NIOSH Web site: www.cdc.gov/niosh/ocas. 

Contact Information on Back ➜
 
 

For more information on dose reconstruction, visit 

www.cdc.gov/niosh/ocas 

E-mail questions to: dcas@cdc.gov

or call 1-877-222-7570 

DHHS (NIOSH) Publication No. 2005-144 

Department of Health and Human Services 

Centers for Disease Control and Prevention
 

National Institute for Occupational Safety and Health